中国血浆蛋白制品的展望  

Prospects for plasma protein products in China

作　　者：菅长永 董方玉 陈晨 周安 周久越 董雪 张翠萍 宋佃卫 周波 马山 JIAN Changyong;DONG Fangyu;CHEN Chen;ZHOU An;ZHOU Ji-uyue;DONG Xue;ZHANG Cuiping;SONG Dianwei;ZHOU Bo;MA Shan(Taibang Biologic Group,Taian 271000,China)

机构地区：[1]泰邦生物集团,山东泰安271000

出　　处：《中国输血杂志》2022年第2期227-232,共6页Chinese Journal of Blood Transfusion

基　　金：山东省科技攻关计划(2019TSLH0408)。

摘　　要：血浆蛋白制品是从健康人血浆提取的用于临床治疗的生物制品,为多种疾病的必需药品。全球以美国、欧洲为首的血浆蛋白新制品的开发已呈全面且深入的状态,这对加快研发中国血浆蛋白新制品具有重要的启示意义。本文总结了国外已投入临床使用而中国尚未国产的血浆蛋白制品的研究现状,分析中国开发这类血浆蛋白制品难点并对其研发种类和应用前景作出展望。Plasma protein products, essential drugs for various clinical diseases, are therapeutic biological products extracted from healthy human plasma. The research and development of new plasma protein products, led by United States and European, has been widely deepened and enhanced. Therefore, accelerating the development of new plasma protein products in China is of great significance. This review summarizes the research and development of plasma protein products that have been marketed abroad but have not produced in China, as well as analyzes the difficulties and prospects of the development of plasma protein products in China.

关 键 词：血浆蛋白制品 人免疫球蛋白 血管性血友病因子复合物 人活化凝血酶原复合物 人抗凝血酶Ⅲ 人C1酯酶抑制剂 

分 类 号：R392-33[医药卫生—免疫学]